Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 6/2017

01-11-2017 | Letter to the Editor

Pure invasive lobular carcinoma versus mixed invasive lobular cancer and invasive ductal carcinoma: metastatic patterns differ?

Author: Kadri Altundag

Published in: Breast Cancer | Issue 6/2017

Login to get access

Excerpt

To The Editor, …
Literature
1.
Inoue M, Nakagomi H, Nakada H, Furuya K, Ikegame K, Watanabe H, et al. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer. Breast Cancer. 2017. doi:10.​1007/​s12282-017-0753-4 (Epub ahead of print).
2.
Bulut N, Dede DS, Sari E, Altundag K. Pure or mixed-type invasive lobular carcinoma? Hum Pathol. 2008;39:112.CrossRef
Metadata
Title
Pure invasive lobular carcinoma versus mixed invasive lobular cancer and invasive ductal carcinoma: metastatic patterns differ?
Author
Kadri Altundag
Publication date
01-11-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 6/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-017-0769-9

Other articles of this Issue 6/2017

Breast Cancer 6/2017 Go to the issue

Author's Reply

Uncertainties remain in the status of internal mammary lymph nodes in breast cancers located in lower inner zone

Case Report

Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy

Original Article

Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size

Original Article

A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer

Original Article

Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer

Original Article

The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits